Pfizer appoints neuroscience research head

pharmafile | June 10, 2010 | Appointment | Research and Development Pfizer, appointment, research and development 

Pfizer has appointed Dr Michael Ehlers chief scientific officer for neuroscience research.

Dr Ehlers most recently served as the George Barth Geller Professor in the Department of Neurobiology at Duke University and as an investigator with the Howard Hughes Medical Institute

Prior to this he served as the director of the neuroproteomics laboratory at Duke University.

He has authored over 60 scientific papers, and has been the recipient of numerous scientific awards, including the NARSAD Distinguished Investigator Award in 2009.

In his new role Dr Ehlers will report to Rod MacKenzie, senior vice president and head of PharmaTherapeutics Research & Development.

Dr MacKenzie said: “Mike is a world class scientist whose deep understanding of neurobiology will be a powerful asset as we build on the progress in our Neuroscience

Research Unit and apply new thinking to deliver novel therapeutics in Alzheimer’s disease, stroke, autism, and schizophrenia.

“His experience in the field and his passion for transforming medical outcomes are a winning combination in helping Pfizer create the industry’s leading pipeline of neuroscience medicines.”

Related Content

anirudh-djo3injpaoe-unsplash_3

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene …

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) …

Pfizer’s Velsipity approved by EC for ulcerative colitis treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …

Latest content